Considerations for Selecting a First-Line Pancreatic Cancer Treatment

Videos — November 14, 2024

Featuring:

Tanios S. Bekaii-Saab, MD
David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ
Shubham Pant, MD
Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX
Michael Pishvaian, MD, PhD
Associate Professor of Oncology
Johns Hopkins University, Washington, DC

In this seventh installment, Michael Pishvaian, MD, PhD, along with Tanios Bekaii-Saab, MD, discuss considerations to keep in mind when selecting first-line treatment options such as FOLFIRINOX or NALIRIFOX for patients with pancreatic cancer.

Featuring:

Tanios S. Bekaii-Saab, MD
David F. and Margaret T. Grohne Professor of Novel Therapeutics for Cancer Research
Chair and Consultant, Division of Hematology and Medical Oncology
Professor, Mayo Clinic College of Medicine and Science, Scottsdale, AZ
Shubham Pant, MD
Professor, GI Medical Oncology
MD Anderson Cancer Center, Houston, TX
Michael Pishvaian, MD, PhD
Associate Professor of Oncology
Johns Hopkins University, Washington, DC

Related Articles